Articles les plus consultés

mardi 3 juillet 2018

Cue Health Receives ISO 13485 Certification

Cue Health Receives ISO 13485 Certification

NEOVACS

Néovacs : Portzamparc juge les résultats cliniques IFN K Lupus globalement très concluants et vise 1,2 euros soit un potentiel de 347%

GEVO...ça repart


Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio

Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio: Introducing ANTHEM® Ankle Fracture and Proximal Humerus Plate Systems

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire: ANTIBE THERAPEUTICS RELEASES SECONDARY ENDPOINT DATA FROM RECENT PHASE 2B GASTROINTESTINAL SAFETY STUDY FOR LEAD DRUG, ATB-346

Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan | Business Wire

Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan | Business Wire: POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, in

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

jeudi 28 juin 2018

22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire

22nd Century宣布新的非转基因极低尼古丁烤烟和白肋烟变种 | Business Wire: (美国商业资讯) -- 22nd Century Group, Inc. (NYSE American: XXII) 是一家植物生物技术公司,也是烟草减害和极低尼古丁烟草领域的领导者。公司今天宣布,已从北卡罗莱纳州立大学(NCSU)获得若干种尼古丁含量极低的烤烟和白肋烟植物品系的排他性授权。上述新植

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q

PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors in Latest Q: PharmaCyte Biotech Discusses Importance of Shrinking Pancreatic Cancer Tumors

mardi 26 juin 2018

recommandations

26/06/2018 | 08:56


    PARIS, 26 juin (Reuters) - Principaux changements de recommandations et/ou d'objectifs de
cours enregistrés mardi à Paris:
    
    * RENAULT           - Morgan Stanley a relevé sa recommandation à "pondération en ligne"
contre "sous-pondérer", avec un objectif de cours de 88 euros. 
    
    * DASSAULT SYSTEMES           - UBS, à "vendre" sur la valeur, a relevé son objectif de
cours à 112 euros contre 87,50 euros.
    
    * ARKEMA          - Barclays, à "surpondérer" sur la valeur, a abaissé son objectif de cours
à 121 euros contre 128 euros. 
    
    * ERYTECH PHARMA           - Jefferies, à l'achat sur la valeur, a abaissé son objectif de
cours à 36 euros contre 39 euros.